P2RY14 and neoplasm: Therefore, antagonism of P2Y14 using recent, more selective and bioavailable compounds represents promising therapeutic and alternative strategies, potentially reducing not only inflammatory interleukins’ secretion and acute neutrophil infiltration, but also impairing the neutrophils’ unwanted detrimental effects over tumor cells’ microenvironment.